Reid Alexander Waldman
CIK: 0002107415
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (11 total)
- Aug 17, 2026MANE
Veradermics, Inc
Sale(S)Direct249 shares at avg. $111.28$28K - Aug 17, 2026MANE
Veradermics, Inc
Exercise(M)Direct3.5K shares at avg. $12.19$42K - Aug 17, 2026MANE
Veradermics, Inc
Sale(S)Direct11.5K shares at avg. $106.72$1.2M - Aug 17, 2026MANE
Veradermics, Inc
Sale(S)Direct25.2K shares at avg. $107.53$2.7M - Aug 17, 2026MANE
Veradermics, Inc
Sale(S)Direct27.5K shares at avg. $108.45$3.0M - Aug 17, 2026MANE
Veradermics, Inc
Sale(S)Direct3K shares at avg. $109.38$328K - Jul 27, 2026ACHV
ACHIEVE LIFE SCIENCES, INC.
Award(A)DirectRestricted Stock Unit (RSU)
16.7K shares- - Jul 27, 2026ACHV
ACHIEVE LIFE SCIENCES, INC.
Award(A)DirectStock Option (right to buy)
25K shares- - May 29, 2026ACHV
ACHIEVE LIFE SCIENCES, INC.
Award(A)DirectStock Option (right to buy)
47.3K shares- - Feb 5, 2026MANE
Veradermics, Inc
Conversion(C)Direct1.4K shares- - Feb 3, 2026MANE
Veradermics, Inc
Award(A)DirectStock Option (Right to Buy)
556.4K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 17, 2026 |  MANE Veradermics, Inc | Sale(S) | 249 | $111.28 | $27,709 | Direct |
| Aug 17, 2026 | MANE Veradermics, Inc | Exercise(M) | 3,452 | $12.19 | $42,080 | Direct |
| Aug 17, 2026 | MANE Veradermics, Inc | Sale(S) | 11,527 | $106.72 | $1,230,161 | Direct |
| Aug 17, 2026 | MANE Veradermics, Inc | Sale(S) | 25,234 | $107.53 | $2,713,412 | Direct |
| Aug 17, 2026 | MANE Veradermics, Inc | Sale(S) | 27,490 | $108.45 | $2,981,291 | Direct |
| Aug 17, 2026 | MANE Veradermics, Inc | Sale(S) | 3,000 | $109.38 | $328,140 | Direct |
| Jul 27, 2026 |  ACHV ACHIEVE LIFE SCIENCES, INC. | Award(A) Restricted Stock Unit (RSU) | 16,700 | - | - | Direct |
| Jul 27, 2026 | ACHV ACHIEVE LIFE SCIENCES, INC. | Award(A) Stock Option (right to buy) | 25,000 | - | - | Direct |
| May 29, 2026 | ACHV ACHIEVE LIFE SCIENCES, INC. | Award(A) Stock Option (right to buy) | 47,250 | - | - | Direct |
| Feb 5, 2026 | MANE Veradermics, Inc | Conversion(C) | 1,437 | - | $0 | Direct |
| Feb 3, 2026 | MANE Veradermics, Inc | Award(A) Stock Option (Right to Buy) | 556,399 | - | - | Direct |
1-11 of 11 transactions
About Waldman Reid Alexander
Waldman Reid Alexander (SEC CIK 0002107415) files insider reports with the SEC as Chief Executive Officer of Veradermics, Inc (MANE) and Director of ACHIEVE LIFE SCIENCES, INC. (ACHV).
Signal8 holds 6 ownership filings by Waldman Reid Alexander (2 Form 3, 4 Form 4), filed between Feb 3, 2026 and Aug 18, 2026. Those filings report 11 transactions, from Feb 3, 2026 to Aug 17, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Waldman Reid Alexander's filings is in NEW HAVEN, CT.
Recent filings by Waldman Reid Alexander
- Aug 17, 2026: Open-market sale of MANE shares (Form 4, code S).
- Aug 17, 2026: Option exercise of MANE shares (Form 4, code M).
- Aug 17, 2026: Open-market sales of MANE shares (4 lines, Form 4, code S).
- Jul 27, 2026: Grants or awards of ACHV derivative securities (2 lines, Form 4, code A).
- May 29, 2026: Grant or award of ACHV derivative securities (Form 4, code A).
Other insiders filing for Veradermics, Inc (MANE)
- Hollander David, Chief R&D Officer
- MONTANOVA CAPITAL, LLC, Director
- Durso Timothy August, Chief Technical Officer
- CHILDS JOHN W, Director
- Seven Fleet Capital Management LP, 10% Owner
- Pance Katarina, Director